Suppliers and packagers for generic pharmaceutical drug: DEXMEDETOMIDINE HYDROCHLORIDE

DEXMEDETOMIDINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390	NDA	BioXcel Therapeutics, Inc.	81092-1120-1	10 POUCH in 1 CARTON (81092-1120-1) / 1 FILM in 1 POUCH (81092-1120-0)	2022-07-01
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390	NDA	BioXcel Therapeutics, Inc.	81092-1120-3	30 POUCH in 1 CARTON (81092-1120-3) / 1 FILM in 1 POUCH (81092-1120-0)	2022-07-01
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390	NDA	BioXcel Therapeutics, Inc.	81092-1180-1	10 POUCH in 1 CARTON (81092-1180-1) / 1 FILM in 1 POUCH (81092-1180-0)	2022-07-01

Dexmedetomidine Hydrochloride: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

This report analyzes key suppliers and the patent landscape for dexmedetomidine hydrochloride, a potent alpha-2 adrenergic agonist used for procedural sedation, anesthesia, and in intensive care units. A thorough understanding of the supplier base and intellectual property protection is critical for R&D investment and market entry strategies.

What is Dexmedetomidine Hydrochloride?

Dexmedetomidine hydrochloride is the active pharmaceutical ingredient (API) for drugs marketed under brand names such as Precedex. It is a selective alpha-2 adrenergic receptor agonist that produces sedative and analgesic effects. Its primary indications include sedation of mechanically ventilated patients in intensive care units and sedation for patients undergoing surgical procedures. The drug’s efficacy and safety profile have led to its widespread adoption in critical care and perioperative settings.

The chemical name for dexmedetomidine hydrochloride is (S)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole hydrochloride. Its molecular formula is C13H16N2·HCl, and it has a molecular weight of 236.74 g/mol. The API is typically manufactured through multi-step organic synthesis, requiring specialized chemical processes and stringent quality control to meet pharmaceutical standards.

Global Manufacturing and Supply Landscape

The production of dexmedetomidine hydrochloride API is concentrated among a limited number of specialized pharmaceutical chemical manufacturers. These suppliers must adhere to Good Manufacturing Practices (GMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The complexity of the synthesis and the demand for high purity necessitate significant technical expertise and investment in manufacturing infrastructure.

Key attributes of the supply landscape include:

• Limited Number of Primary Manufacturers: The synthesis of dexmedetomidine hydrochloride is technically demanding, leading to a relatively small pool of qualified primary manufacturers.
• Geographic Distribution: While manufacturing capabilities exist globally, a significant portion of API production is concentrated in Asia, particularly China and India, due to cost efficiencies and established chemical manufacturing infrastructure. Some European and North American manufacturers also operate in this space, often focusing on higher-value or niche market segments.
• Regulatory Compliance: All suppliers must possess robust quality management systems and adhere to GMP guidelines. This includes rigorous testing for impurities, enantiomeric purity, and stability.
• Supply Chain Volatility: As with many APIs, the supply chain for dexmedetomidine hydrochloride can be susceptible to disruptions stemming from raw material availability, geopolitical events, or regulatory changes.

Major Dexmedetomidine Hydrochloride API Suppliers

Several companies are recognized as significant suppliers of dexmedetomidine hydrochloride API. These entities often have extensive experience in complex organic synthesis and API manufacturing.

• Pais Pharmaceutical (China): A prominent Chinese manufacturer of pharmaceutical intermediates and APIs, including dexmedetomidine hydrochloride. The company emphasizes GMP compliance and has a track record of supplying to international markets.
• SL. Pharma (India): An Indian API manufacturer that produces a range of anesthetic and sedative APIs, with dexmedetomidine hydrochloride being a key product. They operate under stringent GMP conditions.
• Hubei Biocause Pharmaceutical Co., Ltd. (China): This company is a significant producer of APIs and pharmaceutical intermediates. Their portfolio includes products for critical care and anesthesia, such as dexmedetomidine hydrochloride.
• Chemsworth Pvt. Ltd. (India): Another Indian firm involved in the synthesis and supply of various APIs. They have capabilities in producing complex molecules like dexmedetomidine hydrochloride.
• Beijing SL Pharmaceutical Co., Ltd. (China): This entity is often cited as a manufacturer and supplier of dexmedetomidine hydrochloride API.

The sourcing strategy for dexmedetomidine hydrochloride API often involves evaluating suppliers based on:

• Regulatory Filings: Availability of Drug Master Files (DMFs) or Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) can streamline regulatory approval processes for drug product manufacturers.
• Quality Certifications: GMP certifications, FDA inspections, and other quality accreditations are essential.
• Production Capacity and Reliability: The ability of a supplier to consistently meet demand is paramount.
• Pricing and Commercial Terms: Cost-effectiveness remains a significant factor in supplier selection.
• Technical Support: The willingness and ability of a supplier to provide technical assistance and collaborate on process optimization can be valuable.

Patent Landscape for Dexmedetomidine Hydrochloride

The intellectual property surrounding dexmedetomidine hydrochloride is a critical consideration for market entry, generic development, and competitive strategy. Patents can cover the compound itself, specific polymorphs, synthetic processes, formulations, and methods of use.

Compound Patents

The original patent for dexmedetomidine (and its enantiomer, medetomidine) was filed by Orion Corporation. While the basic compound patent has long expired in major markets, subsequent patents may have covered specific aspects of its production or application.

The compound dexmedetomidine is the enantiomer of medetomidine. Medetomidine is a racemic mixture of two enantiomers: dexmedetomidine (the S-enantiomer) and levomedetomidine (the R-enantiomer). Dexmedetomidine is the pharmacologically active enantiomer responsible for the sedative and analgesic effects.

Process Patents

Patents related to the synthesis of dexmedetomidine hydrochloride are particularly relevant for generic manufacturers. These patents aim to protect novel or improved methods of producing the API, often focusing on increased yield, reduced impurities, or more cost-effective routes.

• Enantioselective Synthesis: Developing efficient methods for producing the pure S-enantiomer (dexmedetomidine) is a key area of innovation and patenting. This can involve chiral catalysts, chiral auxiliaries, or resolution techniques.
• Key Intermediates: Patents may also cover the synthesis of crucial intermediate compounds used in the production of dexmedetomidine hydrochloride.
• Crystallization and Polymorphism: Patents can protect specific crystalline forms (polymorphs) of dexmedetomidine hydrochloride or methods for their preparation, as different polymorphs can affect drug stability, solubility, and bioavailability.

Formulation and Method of Use Patents

While the compound patent for dexmedetomidine has expired, companies may hold patents on specific formulations (e.g., specific excipients, concentrations, or delivery systems) or novel methods of using dexmedetomidine hydrochloride. These patents can extend market exclusivity even after the compound patent expires.

• Intravenous Infusion Formulations: Original formulations and extended infusion regimens might have been protected.
• New Indications: Patents could exist for the use of dexmedetomidine hydrochloride in new therapeutic areas or patient populations, although this is less common for a well-established drug.

Patent Expirations and Generic Competition

The expiration of key patents, particularly process patents, opens the door for generic manufacturers to enter the market. The timing of patent expirations is a critical factor for investment decisions in both branded and generic pharmaceutical sectors.

• Orion Corporation: As the originator, Orion Corporation has held significant intellectual property. Their patents for dexmedetomidine have been a cornerstone of their market exclusivity.
• Generic Market Entry: Once key patents expire, generic companies can seek to develop and market their own versions of dexmedetomidine hydrochloride products. This typically involves filing an Abbreviated New Drug Application (ANDA) with the FDA, demonstrating bioequivalence to the reference listed drug (RLD).

The patent landscape for dexmedetomidine hydrochloride is dynamic. Companies looking to enter the market must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate existing patents. This involves searching patent databases for active patents related to the compound, its synthesis, formulation, and use.

Regulatory Considerations

The manufacturing and supply of dexmedetomidine hydrochloride are subject to rigorous regulatory oversight. Compliance with pharmaceutical regulations is non-negotiable for API suppliers and drug product manufacturers.

• Good Manufacturing Practices (GMP): Facilities manufacturing dexmedetomidine hydrochloride API must comply with GMP standards, as defined by regulatory bodies like the FDA (21 CFR Parts 210 and 211), EMA, and others. This ensures product quality, safety, and consistency.
• Drug Master Files (DMFs): API manufacturers often file DMFs with regulatory agencies. A DMF provides confidential detailed information about the manufacturing facility, processes, and quality controls for the API. Drug product manufacturers can then reference the DMF in their own regulatory submissions.
• Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities to ensure ongoing compliance with GMP and other regulations.
• Quality Control and Testing: Stringent quality control measures are required for dexmedetomidine hydrochloride, including assays for purity, identity, related substances, heavy metals, and microbial contamination.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).

Key Takeaways

The supply chain for dexmedetomidine hydrochloride API is characterized by a limited number of specialized manufacturers, with a significant portion of production originating from China and India. Key suppliers must demonstrate robust GMP compliance and possess the technical expertise for complex organic synthesis. The patent landscape, while dominated by older compound patents, can still present hurdles through process and formulation patents, necessitating thorough freedom-to-operate analyses for new entrants. Regulatory compliance, including GMP adherence and the use of DMFs, is paramount for all participants in the dexmedetomidine hydrochloride market.

Frequently Asked Questions

1. What are the primary applications of dexmedetomidine hydrochloride? Dexmedetomidine hydrochloride is primarily used for procedural sedation and as a sedative in intensive care units for mechanically ventilated patients. It also finds application in anesthesia and perioperative care.

2. How does dexmedetomidine hydrochloride's mechanism of action differ from other sedatives? Unlike many other sedatives that act on GABA receptors, dexmedetomidine hydrochloride is a selective alpha-2 adrenergic receptor agonist. This mechanism results in sedation, anxiolysis, and analgesia with a preserved respiratory drive, which is a distinguishing feature.

3. What are the potential risks associated with dexmedetomidine hydrochloride administration? Potential risks include hypotension, bradycardia, transient hypertension, and other cardiovascular effects. Pulmonary complications and central nervous system effects like delirium are also noted.

4. Can dexmedetomidine hydrochloride be administered orally? Dexmedetomidine hydrochloride is typically administered intravenously. Oral administration is not a standard route due to variable absorption and first-pass metabolism. Research into alternative delivery methods continues, but IV remains the primary route.

5. What is the difference between medetomidine and dexmedetomidine? Medetomidine is a racemic mixture containing both dexmedetomidine (the S-enantiomer) and levomedetomidine (the R-enantiomer). Dexmedetomidine is the pharmacologically active S-enantiomer, and it is this specific enantiomer that is used in pharmaceutical products.

Citations

[1] Orion Corporation. (n.d.). Dexmedetomidine. Retrieved from [manufacturer/company website - specific URL would be needed for actual citation] [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry on Drug Master Files. Retrieved from [FDA website - specific URL would be needed for actual citation] [3] European Medicines Agency. (n.d.). Guidance on Active Substance Master Files (ASMFs). Retrieved from [EMA website - specific URL would be needed for actual citation] [4] United States Pharmacopeia. (n.d.). Dexmedetomidine Hydrochloride Monograph. Retrieved from [USP website - specific URL would be needed for actual citation] [5] European Pharmacopoeia. (n.d.). Dexmedetomidine Hydrochloride Monograph. Retrieved from [Ph. Eur. website - specific URL would be needed for actual citation]